Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 548732, 12 pages
http://dx.doi.org/10.1155/2012/548732
Review Article

Emerging Pharmacotherapies for Diabetic Macular Edema

1Department of Ophthalmology, Baylor College of Medicine, 7200-B Cambridge Street, Houston, TX 77030, USA
2Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 311 9th Street North, No. 100, Naples, FL 34102, USA
3Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 Northwest 17th Street, Miami, FL 33136, USA

Received 6 August 2011; Revised 27 October 2011; Accepted 27 October 2011

Academic Editor: R. G. Tilton

Copyright © 2012 Golnaz Javey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Klein, M. D. Knudtson, K. E. Lee, R. Gangnon, and B. E. K. Klein, “The Wisconsin Epidemiologic Study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes,” Ophthalmology, vol. 116, no. 3, pp. 497–503, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. T. A. Ciulla, A. G. Amador, and B. Zinman, “Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies,” Diabetes Care, vol. 26, no. 9, pp. 2653–2664, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. S. T. Knudsen, T. Bek, P. L. Poulsen, M. N. Hove, M. Rehling, and C. E. Mogensen, “Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy,” Diabetes Care, vol. 25, no. 12, pp. 2328–2334, 2002. View at Google Scholar · View at Scopus
  4. T. G. Rotsos and M. M. Moschos, “Cystoid macular edema,” Journal of Clinical Ophthalmology, vol. 2, pp. 919–930, 2008. View at Google Scholar
  5. H. Z. Xu and Y. Z. Le, “Significance of outer blood-retina barrier breakdown in diabetes and ischemia,” Investigative Ophthalmology & Visual Science, vol. 52, pp. 2160–2164, 2011. View at Google Scholar
  6. T. W. Gardner, D. A. Antonetti, A. J. Barber, K. F. LaNoue, and S. W. Levison, “Diabetic retinopathy: more than meets the eye,” Survey of Ophthalmology, vol. 47, supplement 2, pp. S253–S262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. K. Kristinsson, M. S. Gottfredsdóttir, and E. Stefánsson, “Retinal vessel dilatation and elongation precedes diabetic macular oedema,” British Journal of Ophthalmology, vol. 81, no. 4, pp. 274–278, 1997. View at Google Scholar
  8. A. Wurm, T. Pannicke, I. Iandiev et al., “Changes in membrane conductance play a pathogenic role in osmotic glial cell swelling in detached retinas,” American Journal of Pathology, vol. 169, no. 6, pp. 1990–1998, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Ehrlich, A. Harris, T. A. Ciulla, N. Kheradiya, D. M. Winston, and B. Wirostko, “Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process,” Acta Ophthalmologica, vol. 88, no. 3, pp. 279–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Morigi, S. Angioletti, B. Imberti et al., “Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion,” Journal of Clinical Investigation, vol. 101, no. 9, pp. 1905–1915, 1998. View at Google Scholar · View at Scopus
  11. M. Brownlee, “The pathobiology of diabetic complications: a unifying mechanism,” Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005. View at Publisher · View at Google Scholar
  12. N. Shams and T. Ianchulev, “Role of vascular endothelial growth factor in ocular angiogenesis,” Ophthalmology Clinics of North America, vol. 19, no. 3, pp. 335–344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Miyamoto, Y. de Kozak, J. C. Jeanny et al., “Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy,” Diabetologia, vol. 50, no. 2, pp. 461–470, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. W. Cai, S. L. Rook, Z. Y. Jiang, N. Takahara, and L. P. Aiello, “Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth,” Investigative Ophthalmology and Visual Science, vol. 41, no. 7, pp. 1885–1893, 2000. View at Google Scholar · View at Scopus
  15. R. Klein, B. E. K. Klein, S. E. Moss, and K. J. Cruickshanks, “The Wisconsin epidemiologic study of diabetic retinopathy XV: the long term incidence of macular edema,” Ophthalmology, vol. 102, no. 1, pp. 7–16, 1995. View at Google Scholar · View at Scopus
  16. P. Romero-Aroca, M. Baget-Bernaldiz, J. Fernandez-Ballart et al., “Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 94, no. 1, pp. 126–132, 2011. View at Publisher · View at Google Scholar
  17. M. Rodriguez-Fontal, J. B. Kerrison, D. V. Alfaro, and E. P. Jablon, “Metabolic control and diabetic retinopathy,” Current Diabetes Reviews, vol. 5, no. 1, pp. 3–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. Diabetes Control and Complication Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, pp. 977–986, 1993. View at Google Scholar
  19. UK Prospective Diabetes Study Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33,” Lancet, vol. 352, pp. 837–853, 1998. View at Google Scholar
  20. Early Treatment Diabetic Retinopathy Study Research Group, “Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1,” Archives of Ophthalmology, vol. 103, pp. 1796–1806, 1985. View at Google Scholar
  21. M. Nauck, M. Roth, M. Tamm et al., “Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids,” American Journal of Respiratory Cell and Molecular Biology, vol. 16, no. 4, pp. 398–406, 1997. View at Google Scholar · View at Scopus
  22. Diabetic Retinopathy Clinical Research Network, “A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema,” Ophthalmology, vol. 115, pp. 1447–1449, 2008. View at Google Scholar
  23. R. W. Beck, A. R. Edwards, L. P. Aiello et al., “Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema,” Archives of Ophthalmology, vol. 127, no. 3, pp. 245–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. K. Chu, E. J. Chung, O. W. Kwon, J. H. Lee, and H. J. Koh, “Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection,” Eye, vol. 22, no. 7, pp. 895–899, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. L. M. Smithen, M. D. Ober, L. Maranan, and R. F. Spaide, “Intravitreal triamcinolone acetonide and intraocular pressure,” American Journal of Ophthalmology, vol. 138, no. 5, pp. 740–743, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Moshfeghi, P. K. Kaiser, S. J. Bakri et al., “Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 1, pp. 24–29, 2005. View at Google Scholar · View at Scopus
  27. A. R. Bhavsar, M. S. Ip, and A. R. Glassman, “The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials,” American Journal of Ophthalmology, vol. 144, no. 3, pp. 454–456, 2007. View at Publisher · View at Google Scholar
  28. M. A. Bonini-Filho, R. Jorge, J. C. Barbosa, D. Calucci, J. A. Cardillo, and R. A. Costa, “Intravitreal injection versus sub-tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial,” Investigative Ophthalmology and Visual Science, vol. 46, no. 10, pp. 3845–3849, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Chew and S. Trauber, “Diabetic Retinopathy Clinical Research Network, triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study,” Ophthalmology, vol. 114, pp. 1190–1196, 2007. View at Google Scholar
  30. G. J. Jaffe, D. Martin, D. Callanan, P. A. Pearson, B. Levy, and T. Comstock, “Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study,” Ophthalmology, vol. 113, no. 6, pp. 1020–1027, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. “Fluocinolone acetonide ophthalmic- Bausch & Lomb: fluocinolone acetonide envision TD implant,” Drugs RD, vol. 6, no. 2, pp. 116–119, 2005.
  32. J. A. Montero and J. M. Ruiz-Moreno, “Intravitreal inserts of steroids to treat diabetic macular edema,” Current Diabetes Reviews, vol. 5, no. 1, pp. 26–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. A. Campochiaro, G. Hafiz, S. M. Shah et al., “Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert,” Ophthalmology, vol. 117, no. 7, pp. 1393–1399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. P. A. Campochiaro, D. M. Brown, A. Pearson et al., “Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 626–635, 2011. View at Publisher · View at Google Scholar
  35. B. D. Kuppermann, M. S. Blumenkranz, J. A. Haller et al., “Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema,” Archives of Ophthalmology, vol. 125, no. 3, pp. 309–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. J. A. Haller, B. D. Kuppermann, M. S. Blumenkranz et al., “Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema,” Archives of Ophthalmology, vol. 128, no. 3, pp. 289–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. D. S. Boyer, D. Faber, S. Gupta et al., “Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients,” Retina, vol. 31, no. 5, pp. 915–923, 2011. View at Publisher · View at Google Scholar
  38. S. A. Vinores, A. L. Youssri, J. D. Luna et al., “Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease,” Histology and Histopathology, vol. 12, no. 1, pp. 99–109, 1997. View at Google Scholar · View at Scopus
  39. N. L. Derevjanik, S. A. Vinores, W. H. Xiao et al., “Quantitative assessment of the integrity of the blood-retinal barrier in mice,” Investigative Ophthalmology and Visual Science, vol. 43, no. 7, pp. 2462–2467, 2002. View at Google Scholar · View at Scopus
  40. H. Ozaki, H. Hayashi, S. A. Vinores, Y. Moromizato, P. A. Campochiaro, and K. Oshima, “Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates,” Experimental Eye Research, vol. 64, no. 4, pp. 505–517, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. P. A. Campochiaro, “Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412,” Investigative Ophthalmology and Visual Science, vol. 45, no. 3, pp. 922–931, 2004. View at Publisher · View at Google Scholar
  42. E. T. Cunningham Jr., A. P. Adamis, M. Altaweel et al., “A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema,” Ophthalmology, vol. 112, no. 10, pp. 1747–1757, 2005. View at Publisher · View at Google Scholar
  43. M. B. Sultan, D. Zhou, J. Loftus, T. Dombi, and K. S. Ice, “A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema,” Ophthalmology, vol. 118, no. 6, pp. 1107–1118, 2011. View at Publisher · View at Google Scholar
  44. J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. Diabetic Retinopathy Clinical Research Network, “A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema,” Ophthalmology, vol. 114, pp. 1860–1867, 2007. View at Google Scholar
  46. M. Michaelides, A. Kaines, R. D. Hamilton et al., “A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study). 12-month data: report 2,” Ophthalmology, vol. 117, no. 6, pp. 1078–1086, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Michaelides, S. Fraser-Bell, R. Hamilton et al., “Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (bolt study): report 1,” Retina, vol. 30, no. 5, pp. 781–786, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. P. A. Campochiaro, J. S. Heier, L. Feiner et al., “Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study,” Ophthalmology, vol. 117, no. 6, pp. 1102–1112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. D. M. Brown, P. A. Campochiaro, R. P. Singh et al., “Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study,” Ophthalmology, vol. 117, no. 6, pp. 1124–1133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. Q. D. Nguyen, S. M. Shah, J. S. Heier et al., “Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study,” Ophthalmology, vol. 116, no. 11, pp. 2175–2181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. Q. D. Nguyen, S. M. Shah, A. A. Khwaja et al., “Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study,” Ophthalmology, vol. 117, no. 11, pp. 2146–2151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Diabetic Retinopathy Clinical Research Network, M. J. Elman, L. P. Aiello et al., “Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 117, no. 6, pp. 1064–1077, 2010. View at Google Scholar
  55. M. J. Elman, N. M. Bressler, H. Qin et al., “Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 609–614, 2011. View at Publisher · View at Google Scholar
  56. L. P. Aiello, R. W. Beck, N. M. Bressler et al., “Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema,” Ophthalmology, vol. 118, no. 12, pp. e5–e14, 2011. View at Publisher · View at Google Scholar
  57. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar
  58. J. Googe, A. J. Brucker, N. M. Bressler et al., “Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation,” Retina, vol. 31, no. 6, pp. 1009–1027, 2011. View at Publisher · View at Google Scholar
  59. D. M. Brown, Q. D. Nguyen, R. G. Rubio et al., “Ranibizumab for diabetic macular edema (DME): 24-month efficacy and safety results of RISE—a phase 3 randomized controlled trial,” ARVO abstract 6647, 2011.
  60. P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405, 2010. View at Publisher · View at Google Scholar
  61. T. J. Good, A. E. Kimura, N. Mandava, and M. Y. Kahook, “Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents,” British Journal of Ophthalmology, vol. 95, no. 8, pp. 1111–1114, 2011. View at Publisher · View at Google Scholar
  62. S. G. Schwartz, H. W. Flynn Jr., and I. U. Scott, “Endophthalmitis after intravitreal injections,” Expert Opinion on Pharmacotherapy, vol. 10, no. 13, pp. 2119–2126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. A. A. Moshfeghi, P. J. Rosenfeld, H. W. Flynn Jr. et al., “Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center,” Retina, vol. 31, no. 4, pp. 662–668, 2011. View at Publisher · View at Google Scholar
  64. C. A. McCannel, “Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies,” Retina, vol. 31, no. 4, pp. 654–661, 2011. View at Publisher · View at Google Scholar
  65. D. V. Do, Q. D. Nguyen, S. M. Shah et al., “An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema,” British Journal of Ophthalmology, vol. 93, no. 2, pp. 144–149, 2009. View at Publisher · View at Google Scholar
  66. D. V. Do, U. Schmidt-Erfurth, V. H. Gonzalez et al., “The da VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema,” Ophthalmology, vol. 118, no. 9, pp. 1819–1826, 2011. View at Publisher · View at Google Scholar
  67. J. W. Harbour, W. E. Smiddy, H. W. Flynn Jr., and P. E. Rubsamen, “Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane,” American Journal of Ophthalmology, vol. 121, no. 4, pp. 405–413, 1996. View at Google Scholar · View at Scopus
  68. Diabetic Retinopathy Clinical Research Network Writing Committee, J. A. Haller, and H. Qin, “Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction,” Ophthalmology, vol. 117, pp. 1087–1093, 2010. View at Google Scholar
  69. C. J. Flaxel, A. R. Edwards, L. P. Aiello et al., “Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network,” Retina, vol. 30, no. 9, pp. 1488–1495, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. B. D. Kuppermann, E. L. Thomas, M. D. De Smet, and L. R. Grillone, “Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage,” American Journal of Ophthalmology, vol. 140, no. 4, pp. 573–584, 2005. View at Publisher · View at Google Scholar
  71. B. D. Kuppermann, E. L. Thomas, M. D. De Smet, and L. R. Grillone, “Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage,” American Journal of Ophthalmology, vol. 140, no. 4, pp. 585–597, 2005. View at Publisher · View at Google Scholar
  72. F. Lopez-Lopez, M. Rodriguez-Blanco, F. Gómez-Ulla, and J. Marticonera, “Enzymatic vitreolysis,” Current Diabetes Reviews, vol. 5, no. 1, pp. 57–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Gandorfer, “Enzymatic vitreous disruption,” Eye, vol. 22, no. 10, pp. 1273–1277, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Diaz-Llopis, P. Udaondo, F. Arevalo et al., “Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema,” Journal of Ocular Pharmacology and Therapeutics, vol. 25, no. 4, pp. 379–384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Azzolini, A. D'Angelo, G. Maestranzi et al., “Intrasurgical plasmin enzyme in diabetic macular edema,” American Journal of Ophthalmology, vol. 138, no. 4, pp. 560–566, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. M. S. Benz, K. H. Packo, V. Gonzalez et al., “A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy,” Ophthalmology, vol. 117, no. 4, pp. 791–797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. E. I. M. Johnson, M. E. Dunlop, and R. G. Larkins, “Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature,” Current Eye Research, vol. 18, no. 2, pp. 79–82, 1999. View at Google Scholar · View at Scopus
  78. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar · View at Scopus
  79. A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression,” The FASEB Journal, vol. 16, no. 3, pp. 438–440, 2002. View at Google Scholar · View at Scopus
  80. A. C. Amrite, S. P. Ayalasomayajula, N. P. S. Cheruvu, and U. B. Kompella, “Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage,” Investigative Ophthalmology and Visual Science, vol. 47, no. 3, pp. 1149–1160, 2006. View at Publisher · View at Google Scholar
  81. E. Y. Chew, J. Kim, H. R. Coleman et al., “Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema,” Retina, vol. 30, no. 3, pp. 459–467, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. D. A. Gamache, G. Graff, M. T. Brady, J. M. Spellman, and J. M. Yanni, “Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti- inflammatory efficacy,” Inflammation, vol. 24, no. 4, pp. 357–370, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. S. M. Hariprasad, D. Callanan, S. Gainey, Y. G. He, and K. Warren, “Cystoid and diabetic macular edema treated with nepafenac 0.1%,” Journal of Ocular Pharmacology and Therapeutics, vol. 23, no. 6, pp. 585–590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Ducharme and J. M. Weinberg, “Etanercept,” Expert Opinion on Biological Therapy, vol. 8, no. 4, pp. 491–502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. M. K. Tsilimbaris, T. D. Panagiotoglou, S. K. Charisis, A. Anastasakis, T. S. Krikonis, and E. Christodoulakis, “The use of intravitreal etanercept in diabetic macular oedema,” Seminars in Ophthalmology, vol. 22, no. 2, pp. 75–79, 2007. View at Publisher · View at Google Scholar
  86. S. R. Targan, S. B. Hanauer, S. J. H. van Deventer et al., “A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease,” New England Journal of Medicine, vol. 337, no. 15, pp. 1029–1035, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. P. P. Sfikakis, N. Markomichelakis, G. P. Theodossiadis, V. Grigoropoulos, N. Katsilambros, and P. G. Theodossiadis, “Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab,” Diabetes Care, vol. 28, no. 2, pp. 445–447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. A. C. Villablanca, “Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro,” Journal of Applied Physiology, vol. 84, no. 6, pp. 2089–2098, 1998. View at Google Scholar · View at Scopus
  89. C. Heeschen, J. J. Jang, M. Weis et al., “Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis,” Nature Medicine, vol. 7, no. 7, pp. 833–839, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. P. A. Campochiaro, S. M. Shah, G. Hafiz et al., “Topical mecamylamine for diabetic macular edema,” American Journal of Ophthalmology, vol. 149, no. 5, pp. 839–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. W. Li, S. H. Sinclair, and G. T. Xu, “Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema,” Ophthalmic Surgery Lasers and Imaging, vol. 41, no. 1, pp. 18–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Y. Park, N. Takahara, A. Gabriele et al., “Induction of endothelin-1 expression by glucose an effect of protein kinase C activation,” Diabetes, vol. 49, no. 7, pp. 1239–1248, 2000. View at Google Scholar · View at Scopus
  93. C. W. Park, J. H. Kim, J. W. Lee et al., “High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-χB-dependent,” Diabetologia, vol. 43, no. 12, pp. 1544–1553, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. P. Xia, T. Inoguchi, T. S. Kern, R. L. Engerman, P. J. Oates, and G. L. King, “Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia,” Diabetes, vol. 43, no. 9, pp. 1122–1129, 1994. View at Google Scholar · View at Scopus
  95. L. P. Aiello, “The potential role of PKC β in diabetic retinopathy and macular edema,” Survey of Ophthalmology, vol. 47, supplement 2, pp. S263–S269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. R. Donnelly, I. Idris, and J. V. Forrester, “Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research,” British Journal of Ophthalmology, vol. 88, no. 1, pp. 145–151, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Nishizuka, “The molecular heterogeneity of protein kinase C and its implications for cellular regulation,” Nature, vol. 334, no. 6184, pp. 661–665, 1988. View at Google Scholar · View at Scopus
  98. L. P. Aiello, S. E. Bursell, A. Clermont et al., “Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor,” Diabetes, vol. 46, no. 9, pp. 1473–1480, 1997. View at Google Scholar · View at Scopus
  99. M. R. Jirousek, J. R. Gillig, C. M. Gonzalez et al., “(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21- dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene- 1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ,” Journal of Medicinal Chemistry, vol. 39, no. 14, pp. 2664–2671, 1996. View at Publisher · View at Google Scholar · View at Scopus
  100. The PKC-DRS Study Group, “The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial,” Diabetes, vol. 54, no. 7, pp. 2188–2197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. PKC-DRS2 Group, L. P. Aiello, M. D. Davis et al., “Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy,” Ophthalmology, vol. 113, no. 12, pp. 2221–2230, 2006. View at Google Scholar
  102. The PKC-DMES Study Group, “Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial,” Archives of Ophthalmology, vol. 125, no. 3, pp. 318–324, 2007. View at Google Scholar
  103. G. M. Keating and K. F. Croom, “Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus,” Drugs, vol. 67, no. 1, pp. 121–153, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Keech, P. Mitchell, P. Summanen et al., “Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial,” Lancet, vol. 370, no. 9600, pp. 1687–1697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. J. J. Nolan, N. P. Jones, R. Patwardhan, and L. F. Deacon, “Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus,” Diabetic Medicine, vol. 17, no. 4, pp. 287–294, 2000. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Q. Shen, A. Child, G. M. Weber, J. Folkman, and L. P. Aiello, “Rosiglitazone and delayed onset of proliferative diabetic retinopathy,” Archives of Ophthalmology, vol. 126, no. 6, pp. 793–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. E. H. Ryan Jr., D. P. Han, R. C. Ramsay et al., “Diabetic macular edema associated with glitazone use,” Retina, vol. 26, no. 5, pp. 562–570, 2006. View at Publisher · View at Google Scholar